Biomarkers in osteoarthritis: current status and outlook - the FNIH Biomarkers Consortium PROGRESS OA study.
Skeletal Radiol
; 52(11): 2323-2339, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-36692532
Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints' limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigating biomarkers for a prognostic context of use for subsequent qualification through regulatory agencies. This narrative review describes this activity and the work underway, focusing on the PROGRESS OA study.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Osteoarthritis
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Skeletal Radiol
Year:
2023
Document type:
Article
Affiliation country:
Australia
Country of publication:
Germany